




RealRate

# PHARMACEUTICAL 2019

Anixa Biosciences Inc  
Rank 356 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Anixa Biosciences Inc is the variable Net Income, reducing the Economic Capital Ratio by 712% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,352%, being 1,020% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	5,538
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,265
Liabilities, Non-Current	0
Other Assets	838
Other Compr. Net Income	0
Other Expenses	1,677
Other Liabilities	0
Other Net Income	46
Property and Equipment	73
Research and Development	6,813
Revenues	1,112
Selling, General and Administrative Expense	6,912

Output Variable	Value in 1000 USD
Assets	6,449
Liabilities	1,265
Expenses	15,402
Stockholders Equity	5,183
Net Income	-14,243
Comprehensive Net Income	-14,243
Economic Capital Ratio	-1,352%